Axsome's depression drug enters competitive market after U.S. approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall St set for subdued open as markets monitor Hormuz situation
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil rises nearly 2% as Iran tempers hopes of Hormuz reopening
- HPE stock surges 5% as Morgan Stanley upgrades, pointing to ~30% upside
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Axsome Therapeutics (AXSM) Rallies After Auvelity Gains FDA Approval
August 19, 2022 2:13 PM EDTBiopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) surged Friday after it announced that the U.S. Food and Drug Administration (FDA) has approved Auvelity for treating major depressive disorder (MDD) in adults.
Axsome shares hit a high of $61.11 following the news. They have since... More
Cowen Reiterates Outperform, $130 PT on Axsome Therapeutics (AXSM) Following FDA Approval
August 19, 2022 10:39 AM EDTCowen analyst Joseph Thome reiterated an Outperform rating and $130.00 price target on Axsome Therapeutics (NASDAQ: AXSM) following news that AXS-05 (Auvelity) has been approved for the treatment of MDD nearly one year after the therapy's initial PDUFA date.
The analyst... More
